Neogenomics (NEO) Share-based Compensation (2010 - 2026)

Neogenomics (NEO) has reported Share-based Compensation for 17 consecutive years, with $9.6 million the latest figure, recorded in Q1 2026.

• Share-based Compensation for Q1 2026 came in at $9.6 million, down 10.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $40.2 million (up 109.56% YoY), and the FY2025 annual result was $41.3 million, up 23.65% from the prior year.
• Share-based Compensation was $9.6 million for Q1 2026 at Neogenomics, up from $8.0 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $12.2 million in Q2 2025 and troughed at $100000.0 in Q2 2024.
• Average Share-based Compensation over 5 years is $7.4 million, with a median of $7.9 million recorded in 2024.
• Year-over-year, Share-based Compensation tumbled 60.69% in 2023 and soared 12114.0% in 2025.
• Over 5 years, Share-based Compensation stood at $4.7 million in 2022, then soared by 49.9% to $7.0 million in 2023, then grew by 19.14% to $8.3 million in 2024, then decreased by 3.43% to $8.0 million in 2025, then increased by 19.82% to $9.6 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $9.6 million in Q1 2026, $8.0 million in Q4 2025, and $10.3 million in Q3 2025.